March 03, 2019
SwissDRG clarifies add-on reimbursement for Elbasvir and Grazoprevir
On February 14, 2020, the entity that manages the Swiss DRG system, SwissDRG, clarified the add-on reimbursement ZE-2020-129 for Elbasvir and Grazoprevir.

This was done because, at the end of last year, the drug Elbasvir and Grazoprevir (oral) was included in the list of drugs, and therefore the provisions of articles 71a and 71b of the Ordinance on health insurance (OAMal/KVV) are not applicable to this additional reimbursement.

The add-on reimbursement can only be billed for the oral use of preparations, with the combination of 100 mg Grazoprevir / 50 mg Elbasvir (e.g., Zepatier®). The add-on reimbursement amount ranges from CHF 1,079.08 to 7,913.24, depending on the unit dose.

More details can be seen in Italian (switch to German or French in the top-right corner) here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Subscribe to newsletter
Subscribe to our newsletter to get regular updates from us on the changes of reimbursement systems (>100 reimbursement stakeholders in 12 EU countries)